Literature DB >> 9149073

Long-term follow-up of Lambert-Eaton syndrome treated with intravenous immunoglobulin.

S Muchnik1, A S Losavio, A Vidal, L Cura, C Mazia.   

Abstract

Recent reports have shown that patients with Lambert-Eaton myasthenic syndrome (LEMS) improve transiently after high-dose intravenous immunoglobulin (IVIG) administration. Information about the usefulness of IVIG for long-term treatment is rather scanty. Our findings demonstrate the efficacy of monthly IVIG courses at a dose of 0.4 g/kg/day for 5 days, in a 41-year-old patient with LEMS without detectable malignancy. Improvement in limb strength, peak expiratory flow rate, and electrophysiological parameters, as well as clinical signs following IVIG, was evident as early as 7 days after the first course and is still maintained at 24-months follow-up.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9149073     DOI: 10.1002/(sici)1097-4598(199706)20:6<674::aid-mus3>3.0.co;2-5

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  10 in total

Review 1.  [Use of i.v. immunoglobulins in neurology. Evidence-based consensus].

Authors:  M Stangel; R Gold
Journal:  Nervenarzt       Date:  2004-08       Impact factor: 1.214

Review 2.  Intravenous immunoglobulin therapy in neurological diseases during pregnancy.

Authors:  Isabel Ringel; Uwe K Zettl
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

Review 3.  Intravenous immunoglobulin in neurological disease: a specialist review.

Authors:  C M Wiles; P Brown; H Chapel; R Guerrini; R A C Hughes; T D Martin; P McCrone; J Newsom-Davis; J Palace; J H Rees; M R Rose; N Scolding; A D B Webster
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

Review 4.  IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status.

Authors:  Isabel Illa
Journal:  J Neurol       Date:  2005-05       Impact factor: 4.849

Review 5.  Intravenous immunoglobulin therapy in paraneoplastic neurological syndromes.

Authors:  Raymond Voltz
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

6.  Lambert-Eaton Myasthenic Syndrome.

Authors:  John Newsom-Davis
Journal:  Curr Treat Options Neurol       Date:  2001-03       Impact factor: 3.598

Review 7.  Treatment for Lambert-Eaton myasthenic syndrome.

Authors:  Michael Keogh; Saam Sedehizadeh; Paul Maddison
Journal:  Cochrane Database Syst Rev       Date:  2011-02-16

8.  Clinical applications of immunoglobulin: update.

Authors:  Marcia Cristina Zago Novaretti; Carla Luana Dinardo
Journal:  Rev Bras Hematol Hemoter       Date:  2011

Review 9.  Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome.

Authors:  Tyler B Tarr; Peter Wipf; Stephen D Meriney
Journal:  Mol Neurobiol       Date:  2014-09-09       Impact factor: 5.590

Review 10.  Lambert-Eaton Myasthenic syndrome: early diagnosis is key.

Authors:  Trajche Ivanovski; Francesc Miralles
Journal:  Degener Neurol Neuromuscul Dis       Date:  2019-05-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.